Anti–Tumor Necrosis Factor-Alpha Improves Myocardial Recovery After Ischemia and Reperfusion  by Gurevitch, Jacob et al.
EXPERIMENTAL STUDIES
Anti–Tumor Necrosis Factor-Alpha Improves Myocardial Recovery
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Objectives. This study sought to assess the importance of locally
released or paracrine myocardial tumor necrosis factor-alpha
(TNF-alpha) in the evolution of postischemic myocardial dysfunc-
tion and to use immunohistochemical studies to localize TNF-
alpha within the myocardium.
Background. TNF-alpha is implicated as a systemic mediator in
the development of myocardial ischemia–reperfusion injury by
promoting leukocyte myocardial infiltration, and it has been
shown to originate from noncardiac peripheral mononuclear cells.
We have recently documented in a blood-free environment the
release of TNF-alpha from the ischemic-reperfused myocardium.
Methods. Isolated rat hearts undergoing 1 h of global
cardioplegia-induced ischemia and 30 min of reperfusion were
investigated with use of the modified Langendorff model. Hearts
were randomly divided into three subgroups: group A, control
group; and groups B and C, isolated hearts receiving cardioplegic
solution containing monoclonal hamster antimurine TNF-alpha
antibodies (group B) or hamster IgG (group C).
Results. Significant amounts of TNF-alpha were detected in
group A and group C effluent on 1 min of reperfusion (752 6 212
and 958 6 409 pmol/ml, respectively). However, in group B,
TNF-alpha was below detectable levels. In this group, postisch-
emic left ventricular peak systolic pressures, first derivative of the
rise in left ventricular pressure (dP/dtmax), pressure-time integral,
coronary flow and O2 consumption improved (analysis of variance
[ANOVA] p < 0.0001 for all variables) compared with values in
groups A and C; creatine kinase levels decreased (p < 0.005); and
myocardial structure was preserved. Immunohistochemical stain-
ing localized TNF-alpha to cardiac myocytes and to endothelial
cells.
Conclusions. Anti–TNF-alpha neutralizes local TNF-alpha re-
lease from cardiac myocytes after ischemia and improves myocar-
dial recovery during reperfusion, indicating that postischemic
paracrine TNF-alpha release plays an active role in myocardial
dysfunction.
(J Am Coll Cardiol 1997;30:1554–61)
©1997 by the American College of Cardiology
Tumor necrosis factor-alpha (TNF-alpha), or cachectin, is a
polypeptide hormone considered a common systemic mediator
of stress-induced situations such as septic shock during endo-
toxemia (1), wasting in cancer (2) and a variety of cardiac
disease states (3–7). It was first introduced in 1975 as an
endotoxin-induced serum factor (8). Experimental evidence
(9) has recently shown that TNF-alpha is also involved in the
pathogenesis of myocardial ischemia-reperfusion injury.
The current hypothesis is that TNF-alpha is primarily
produced by noncardiac-activated macrophages in response to
ischemia and reperfusion (9–11). Support for this hypothesis is
the finding of increased levels of TNF-alpha in the peritoneal
macrophages collected from rats subjected to myocardial
ischemia–reperfusion injury (9). The circulating TNF-alpha
stimulates intracellular adhesion molecule-1 (ICAM-1) expres-
sion on cardiac myocytes (12), which in turn promotes adhesive
interaction between transmigrated neutrophils and cardiac
myocytes of the reperfused myocardium (13,14). The end
result is the release of harmful substances, such as oxygen free
radicals, leukotrienes and cytokines from these neutrophils
(15–17).
In contrast to the preceding, we (18) recently observed that
rat myocardium releases significant amounts of TNF-alpha
after prolonged ischemia. This latter observation raises the
possibility that myocardial dysfunction that occurs after
ischemia–reperfusion may develop directly in response to the
compartmentalized production of TNF-alpha in the heart, as
opposed to the systemic production of TNF-alpha by circulat-
ing mononuclear cells.
To examine this new pathway we tested whether treatment
with anti–TNF-alpha monoclonal antibodies given before isch-
emia can attenuate ischemia-reperfusion myocardial injury in a
From the Department of Thoracic and Cardiovascular Surgery Ichilov
Hospital and Institute of Pathology, Diagnostic and Research Cancer Center,
Elias Sourasky–Tel-Aviv Medical Center, Tel-Aviv; and *Felsenstein Medical
Research Center, Petah-Tikva, Israel. This study was supported by the Research
Fund of the Department of Thoracic and Cardiovascular Surgery, Elias
Sourasky–Tel-Aviv Medical Center.
Manuscript received August 12, 1996; revised manuscript received July 14,
1997, accepted August 5, 1997.
Address for correspondence: Dr. Jacob Gurevitch, Department of Thoracic
and Cardiovascular Surgery, Ichilov Hospital, Elias Sourasky–Tel-Aviv Medical
Center, 6 Weizman Street, Tel-Aviv 64239, Israel.
JACC Vol. 30, No. 6
November 15, 1997:1554–61
1554
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00328-8
blood-free environment. The second goal of this study was to
identify cellular origins of TNF-alpha production within the
myocardium by using immunohistochemical strategies.
Methods
Male Wistar rats were anesthetized by intraperitoneal
injection of pentobarbital sodium (30 mg/kg body weight) and
heparinized. Their hearts were rapidly excised, immersed in
cold saline solution (4°C) with heparin, and mounted on the
stainless-steel cannula of a modified Langendorff perfusion
apparatus.
Retrograde aortic perfusion was initiated at a perfusion
pressure of 85 mm Hg with an oxygenated modified Krebs-
Henseleit (KH) buffer solution of the following composition
(mmol/liter): NaCl 118, KCl 4.7, CaCl 2.0, MgSO4 7H2O 1.2,
KH2PO4 1.2, glucose 11.1 and NaHCO3 25. The perfusate was
bubbled continuously with 95% O2 and 5% CO2, maintaining
a pH of 7.4 to 7.5. Values of PO2 and PCO2 in the perfusion
solution were 450 to 550 mm Hg and 25 to 30 mm Hg,
respectively.
The heart temperature was monitored by a thermistor
implanted in the right ventricular wall and carefully main-
tained at 37°C or 31°C (at ischemia) by water jacketing the
perfusate reservoir and the isolated heart. The right atrium
was removed, and the heart was paced to 300 beats/min at 4 V
with use of an external pacemaker (Devices Limited, Implants
Division, type E4162), ensuring identical heart rates for all
hearts. A water-filled latex balloon was placed in the left
ventricular cavity through a small incision in the left atrium
and was connected to a Mennen Medical PI 32284 pressure
transducer. The balloon was tied and inflated to a volume
that produced 0 mm Hg diastolic pressure. Zero calibration of
the pressure transducer was examined throughout the experi-
ment.
Left ventricular peak systolic pressure, time to peak systolic
pressure, relaxation time, the first derivative of the rise and fall
in left ventricular pressure (dP/dtmax, dP/dtmin), the area
calculated under the left ventricular developed pressure curve
(pressure-time integral) and coronary flow were measured.
These variables were continuously recorded, and measure-
ments were taken at 10-min intervals.
Ethics. All animals received humane care as described in
“Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the Na-
tional Academy of Sciences and published by the National
Institutes of Health (NIH publication no. 80-23, revised 1985).
Protocol. Twenty-seven rats were randomly divided into
three subgroups of nine animals each. Group A (the control
group), undergoing ischemia and reperfusion; group B, iso-
lated hearts receiving hamster antimurine TNF-alpha mono-
clonal antibodies (anti-TNF mAb) in the cardioplegic solution
(50 mg/ml, total dose given 1.5 mg); and group C, isolated
hearts receiving hamster IgG in the cardioplegic solution (50
mg/ml, total dose given 1.5 mg), serving as additional control to
group B.
Control measurements were recorded after a 15-min period
of stabilization, and each heart was perfused thereafter for
30 min. Warm cardioplegic solution was administered for
2 min (37°C, perfusion pressure 73 mm Hg, KCl 5 16
mEq/liter in KH solution), and a 60-min period of global
ischemia at 31°C was applied to the arrested heart.
Creatine kinase (CK) activity was measured spectophoto-
metrically in the effluent at 1 min of reperfusion after ischemia.
Measurements of left ventricular function were taken every
10 min during the 30 min of the reperfusion period. Finally the
hearts were dried at 90°C for 24 h to achieve a constant dry
weight. Throughout the study, experiments were alternated
between the control and the experimental limbs to avoid bias
or differences in results.
TNF-alpha determination. Efferent perfusate fluid sam-
ples for TNF-alpha measurements were withdrawn at baseline
measurements (15 min after stabilization), after 30 min of
perfusion, immediately after ischemia (1st ml), at 10 minutes
of reperfusion and at termination of reperfusion (30 min); the
samples were then immediately stored at 270°C until assay.
TNF-alpha levels were determined on the basis of cytotoxic
activity assay on mouse L929 cells according to the methods
described by Wallach (19) and Yuhas et al. (20). Each assay
included a standard curve of recombinant human TNF-alpha
(specific activity 2.5 3 107 IU/mg protein) kindly provided by
Dr. Armat from Reprogen Ltd, Rehovot, Israel. The limit of
detection was 1 U/ml.
Antibodies. Anti-TNF mAb was purchased from Genzyme;
;50 to 100 ng of this antibody will completely neutralize 1 U
of murine TNF. Anti-TNF mAb was previously recognized to
completely neutralize rat TNF (21,22). For group C control
rats we used hamster IgG purchased from Jackson.
Oxygen consumption. Perfusate afferent and efferent gases
were measured after 15 min of stabilization, 1 min before
administration of cardioplegic solution, at 10 min of reperfu-
sion and at the end of reperfusion. Samples were withdrawn
from the Langendorff perfusion apparatus and from the right
ventricle by using a tiny polyethylene catheter inserted through
a pulmonary artery incision. O2 consumption was calculated by
using the following formula (23):
Abbreviations and Acronyms
ANOVA 5 analysis of variance
anti-TNF mAb 5 hamster antimurine tumor necrosis factor-alpha
monoclonal antibodies
CK 5 creatine kinase
dP/dtmax 5 first derivative of the rise in left ventricular pressure
dP/dtmin 5 first derivative of the fall in left ventricular pressure
ICAM-1 5 intracellular adhesion molecule-1
KH 5 Krebs-Henseleit
TNF 5 tumor necrosis factor
TNFR1 5 tumor necrosis factor receptor-1
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O2 consumption (mmol/h per g)
5
Arteriovenous O2 tension (mm Hg)
760 (mm Hg)
3
Solubility of O2 at 37°C (ml/ml H2O)
22.4 (ml/mmol)
3
Coronary flow (ml/h)
Dry weight of heart (g)
.
Immunohistochemical localization of myocardial TNF-
alpha. To visualize the presence and anatomic localization of
TNF-alpha within the myocardium, immunohistochemical
studies were performed in three groups of isolated hearts:
group 1, four hearts undergoing 1 h of cardioplegic ischemia;
group 2, four hearts undergoing similar ischemia receiving
anti-TNF mAb in the cardioplegic solution (50 mg/ml, total
given dose of 1.5 mg; hearts from these two groups were freshly
excised immediately after ischemia); and group 3, four isolated
hearts excised after 120 min of perfusion (without ischemia)
that served as a control group.
Excised hearts were fixed in 10% neutral buffered formalin
(Z-fix; Anatech, Ltd.) at room temperature for 18 to 24 h. The
tissue was then dehydrated, embedded in paraffin and sec-
tioned (5-mm sections) in a standard manner. Immunohisto-
chemical studies were performed by using a streptavidin-biotin
immunoperoxidase method according to the manufacturer’s
instructions (Zymed Lab. Inc.). All reagents were prepared
with a dilluent consisting of Tris buffer pH 7.6 supplemented
with 0.2% monolaurate (Tween 20) and 1% bovine serum
albumin. To minimize background staining, all sections were
first blocked with normal goat serum for 10 min at room
temperature. The slides were incubated with two concentra-
tions (1:100 or 1:250) of primary antibody directed against
human TNF-alpha (Genzyme). Sections were allowed to incu-
bate in a humidified chamber for 1 h at room temperature. The
slides were then rinsed in Tris buffer and incubated for 10 min
at room temperature with a biotin-conjugated goat anti-rabbit
secondary antibody. To rule out nonspecific antibody staining,
slides for negative control were stained with 1) normal nonim-
mune rabbit serum (1:100 dilution) instead of the primary
antibody (n 5 4); 2) secondary antibody alone (1:100 dilution,
n 5 4). After blocking the endogenous peroxidase activity with
methanol and hydrogen peroxide, the slides were incubated
with streptavidin-peroxidase complex. Diaminobenzidine was
used as a chromogen to visualize the presence and distribution
of TNF-alpha. Sections were then rinsed in Tris buffer coun-
terstained in hematoxylin, dehydrated, cleared and mounted
with use of a synthetic mounting medium.
To compare the intensity of TNF-alpha expression in a
variety of cell types of the myocardium, relative intensity of
staining was assayed by two independent observers. In this
assay TNF-alpha staining ranged from the lowest intensity of
positive staining (scored as 1) to very intense, dark staining
(scored as 3). No staining was scored as 0. Mean value 6 SE
was calculated. Three or four consecutive tissue sections of
each heart were assayed. The tissue sections of the same hearts
were used for histologic studies using hematoxylin-eosin stain-
ing.
Statistics. Results are presented as mean value 6 SE. To
avoid differences in baseline values, the value of the 1st 15 min
of contraction of each heart was used as the heart’s individual
control. All control values for left ventricular function, coro-
nary effluent and O2 consumption were considered as 100%.
Between-group cytotoxic activity, CK levels and immunostain-
ing intensity measurements were analyzed by paired Student t
test. Two-way analysis of variance (ANOVA) with repeated
measurements for drug and time effect was calculated for all
variables before and after ischemia. Significance was estab-
lished at the level of p , 0.05.
Results
All baseline variables taken after 15 min of stabilization
were statistically similar for the three groups of hearts (Table
1). Moreover, the three groups maintained comparable vari-
ables during 30 min of the preischemic perfusion period (Fig.
1).
TNF-alpha release. Significant amounts of TNF-alpha
were detected in group A and C effluent on the 1st min of
reperfusion (752 6 212 and 958 6 409 pmol/ml, respectively).
In all other samples taken during baseline measurements (after
15 min of stabilization), before ischemia (after 30 min of
perfusion) and at 10 and 30 minutes of reperfusion, TNF-alpha
was below detectable levels. All effluent cytotoxic activity was
neutralized by preincubation with anti-TNF-alpha mAb: 62.5
ng of antibodies completely neutralized 1 U of effluent TNF
(n 5 6), whereas 31.25 ng of antibodies provided 80 6 3% of
complete neutralization (n 5 6, p , 0.002), thus confirming
that the cytotoxic activity was due to TNF-alpha. In all samples
withdrawn from group B effluent (hearts treated with anti-TNF
mAb), TNF-alpha was below detectable levels.
For additional evidence that primary TNF-alpha is indeed
synthesized de novo by the isolated heart, we constructed
another study subgroup. Isolated rat hearts (n 5 4) received a
Table 1. Baseline Measurements
Group A
(control group)
Group B
(anti-TNF)
Group C
(IgG)
Rat weight (g) 381 6 4.9 392 6 3.0 384 6 6.5
Heart weight (g) 1.24 6 0.03 1.25 6 0.02 1.26 6 0.04
Dry heart weight (g) 0.2 6 0.05 0.22 6 0.02 0.2 6 0.01
Peak systolic pressure
(mm Hg)
128 6 2.1 119 6 3.8 118 6 4.2
dP/dtmax (mm Hg/s) 4,042 6 390 4,118 6 215 4,043 6 171
dP/dtmin (mm Hg/s) 22,975 6 190 23,016 6 222 22,996 6 150
Time-pressure integral
(mm Hgzs)
8.89 6 0.34 8.51 6 0.37 7.86 6 0.54
Coronary flow
(ml/min)
19.1 6 0.86 17.8 6 1.03 20 6 1.50
O2 consumption
(mmol/h per g)
1.58 6 0.05 1.55 6 0.04 1.67 6 0.04
Data presented are mean values 6 SE. dP/dtmax and dP/dtmin 5 first
derivative of the rise and fall, respectively, of left ventricular pressure; TNF 5
tumor necrosis factor.
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nonspecific protein synthesis blocking agent (1.5 mg of cyclohex-
imide) in the cardioplegic solution just before ischemia. After 1 h
of ischemia, effluent TNF-alpha was below detectable levels.
Hemodynamic changes. After ischemia, a significant dete-
rioration in preischemic values was observed in all group A and
C myocardial performance variables (Fig. 1). Hearts treated
with anti-TNF mAb (group B) had a significant improvement
over control group values in postischemic left ventricular peak
systolic pressures (Fig. 1A), dP/dtmax (Fig. 1B) and dP/dtmin,
the area calculated under the left ventricular developed pres-
sure curve (pressure-time integral, Fig. 1C), coronary flow
(Fig. 1D) and O2 consumption (Fig. 1E) (ANOVA with
repeated measurements, p , 0.0001 for all of these variables).
The significant improvement in myocardial recovery of group
B hearts was already observed at 10 min of reperfusion, and
was maintained thereafter.
Group B postischemic effluent CK levels were significantly
lower than those in groups A and C (42.7 6 2.2 vs. 73.2 6 5.6
and 67.0 6 4.9 U/liter, respectively, p , 0.005). Adding IgG to
the cardioplegic solution (group C, serving as an additional
biologic control) did not protect against the ischemia-
reperfusion myocardial injury, and no hemodynamic and en-
zymatic variables differed significantly from those in group A
(control group).
Intramyocardial immunochemical localization of TNF-
alpha. TNF-alpha immunostaining was not detected in the
hearts after 2 h of KH nonischemic perfusion (Fig. 2A). There
was obvious TNF-alpha immunostaining in hearts after 1 h of
Figure 1. Hemodynamic performance of isolated rat hearts: control
group (open bars), hearts treated with hamster anti-murine anti–TNF-
alpha monoclonal antibodies in cardioplegia (solid bars) and hearts
treated with hamster IgG in cardioplegia (hatched bars). Preischemic
peak systolic pressures (A), dP/dt max (B), pressure-time integral (C),
coronary flow (D) and oxygen consumption (E) appear stable, with no
differences among the three groups. Results are represented as percent
of baseline measurements of each heart. After ischemia, the control
and IgG groups portrayed a significant deterioration in myocardial
performance, whereas hearts treated with 50 mg/ml of anti–TNF-alpha
antibodies in the cardioplegia exhibited improved recovery compared
with control and IgG groups (ANOVA, p , 0.0001 for all variables).
*p , 0.001 versus control and IgG groups. Rep 5 reperfusion.
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ischemia (Fig. 2B). TNF-alpha staining was primarily localized
in cardiac myocytes (immunostaining intensity 2.79 6 0.06)
and, to a lesser degree, in the endothelium of myocardial
vessels (immunostaining intensity 1.35 6 0.03, p , 0.001).
Smooth muscles of the vessels were not immunostained.
TNF-alpha staining was not detected in hearts pretreated with
anti TNF mAb in the cardioplegic solution (group B),
indicating compete neutralization of TNF-alpha synthesized
during ischemia (Fig. 2C). There was no nonspecific myo-
cardial immunostaining for TNF-alpha when ischemic
hearts were incubated with either normal nonimmune rabbit
serum instead of the primary antibody, or with secondary anti-
body alone (two groups of negative controls; data not shown).
Figure 2. Immunolocalization of myocardial TNF-alpha and myocar-
dial histology in isolated rat hearts. Hearts undergoing 120 min of
normal perfusion do not show immunostaining for TNF-alpha (A) and
present normal myocardial structure (D). Hearts undergoing 1 h of
global cardioplegic ischemia demonstrate prominent immunostaining
for TNF-alpha in the cardiac myocytes (B) and ischemic myocardial
damage (edema, loss of cardiac myocytes nuclei and disintegration of
muscle fibers [E]). When hamster anti-murine anti–TNF-alpha mono-
clonal antibodies are added to cardioplegia given before ischemia,
immunostaining for TNF-alpha is negative (C), and myocardial struc-
ture is preserved compared with that in untreated ischemic hearts (F).
The apical portion was incubated with a primary antibody directed
against human TNF-alpha and biotin-conjugated goat anti-rabbit
secondary antibody. The basal portion was stained with hematoxylin-
eosin stain for overall morphology. All photographs were obtained at
3400.
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Histologic studies. The tissue sections of the same hearts
were used for histologic studies using hematoxylin-eosin stain-
ing. After 2 h of nonischemic KH perfusion, myocardial
structure was preserved (Fig. 2D), whereas after 1 h of
cardioplegia-induced ischemia, myocardial damage was ob-
served (Fig. 2E). Hearts pretreated with anti-TNF mAb in the
cardioplegic solution (group B) demonstrated almost complete
restoration of normal histologic features (Fig. 2F).
Discussion
In this study significant amounts of TNF-alpha were de-
tected in the effluent of the isolated rat heart undergoing
cardioplegia-induced arrest and prolonged ischemia. Immuno-
histochemical studies localized TNF-alpha to cardiac myocytes
and, to a lesser extent, to vascular endothelial cells. Primary
TNF-alpha was produced during ischemia and was detectable
only in the 1st min of reperfusion. We have proved here that
this paracrine TNF-alpha release plays a dominant role in the
ischemia-reperfusion injury, as neutralization with specific
monoclonal antibodies against this cytokine (given before
ischemia, in the cardioplegic solution) completely eliminated
TNF-alpha from the effluent and concurrently attenuated the
postischemic myocardial injury. Anti-TNF mAb improved the
postischemic recovery and myocardial mechanical perfor-
mance, decreased the amount of cellular necrosis and pre-
served myocardial structure.
TNF-alpha: a myocardial depressant factor. TNF-alpha is
a proinflammatory cytokine with potent negative inotropic
properties. Elevated levels of serum TNF-alpha were associ-
ated with depressed myocardial function (24). These TNF-
alpha concentration- and time-dependent negative inotropic
effects were reversible (25), and only recently (26) appeared to
be initiated by the activation of TNFR1 cell surface receptors.
Treatment with anti-TNF mAb was shown to prevent myocar-
dial dysfunction during experimental burn shock (27) and in
several cardiac pathologic conditions such as acute viral myo-
carditis (3) and acute allograft rejection (28). The involvement
of serum TNF-alpha in myocardial ischemia–reperfusion in-
jury in the rat was indicated, as passive systemic immunization
against this TNF-alpha increased survival rates (15).
Primary intramyocardial synthesis of TNF-alpha. In pre-
vious studies TNF-alpha was assumed to originate not from the
ischemic heart but from systemic activated macrophages. We
have demonstrated that primary TNF-alpha is synthesized in
the ischemic isolated heart. As no TNF-alpha immunoreactiv-
ity was shown in the myocardium of 2 h of perfused control
hearts, TNF-alpha cannot be derived in the cytoplasmic pool.
In our study we deliberately used a blood-free perfusion model
to exclude the possibility of involvement of systemic blood-
borne factors in TNF-alpha production. However, we noted
additional evidence that TNF-alpha is indeed synthesized de
novo by the isolated heart in a relatively short ischemic time:
Hearts treated with cycloheximide did not release TNF-alpha
after 1 h of global ischemia.
By performing in vivo experimental regional ischemia,
Herskowiz et al. (29) found TNF-alpha messenger ribonucleic
acid (mRNA) expression after only 30 min in the postischemic
reperfused myocardium. Kapadia et al. (30) demonstrated that
when isolated hearts were stimulated with endotoxin in vitro,
primary TNF messenger ribonucleic acid (mRNA) expression
occurred within 30 min.
Sources of intramyocardial TNF-alpha. Immunohisto-
chemical studies localized TNF-alpha to cardiac myocytes and
to a lesser extent to endothelial cells and not to smooth muscle
cells. TNF-alpha immunostaining was not apparent either in
nonischemic normally perfused hearts or in hearts pretreated
with anti-TNF mAb. The former findings emphasize the
importance of ischemia to primary TNF-alpha induction or
synthesis, whereas the latter strengthen the notion that TNF-
alpha was neutralized not only in the effluent but probably in
the tissue as well, and therefore its postischemic paracrine
deleterious effect was eliminated. It is not unlikely that TNF-
alpha release from the heart is derived quantitatively from
different sources in various situations. Kapadia et al. (30)
found TNF-alpha in cardiac myocytes, endothelial and smooth
muscle cells in endotoxin-stimulated isolated hearts; however,
Herskowitz et al. (29) found immunostaining of TNF-alpha in
microvessels.
Possible mechanisms for anti-TNF myocardial protection.
TNF-alpha is probably a linking milestone in the evolution of
the ischemia-reperfusion injury. The negative inotropic effect
of TNF-alpha is associated with decreased levels of intracellu-
lar calcium during the systolic contraction sequence (25) and
with decreased contractility. TNF-alpha is involved in the
release of free radicals from the myocardium (31), a self-
amplifying process, as free radical production has been shown
(32) to further increase TNF-alpha. TNF-alpha also acts by
way of the NO pathway and causes myocardial dysfunction
after ischemia (33).
Monoclonal antibodies against TNF-alpha (given in car-
dioplegic solution) saturate the extracellular environment of
the ischemic heart, neutralize the TNF-alpha (released by the
ischemic myocardium) and probably prevent the binding of
TNF-alpha to TNFR1 receptors. Thus, a reasonable explana-
tion for the cardioprotective effect of anti-TNF mAb might be
that by eliminating TNF-alpha from the ischemic cascade, the
entire snowball effect is significantly decreased, and therefore
ischemic damage is also decreased. By a similar mechanism,
soluble TNF-alpha binding proteins were shown (34) to mod-
ulate the negative inotropic properties of TNF-alpha. How-
ever, we do not believe that TNF-alpha is the only factor
responsible for the evolution of ischemic damage. By eliminat-
ing other factors (e.g., free radical scavenging) postischemic
myocardial recovery is also improved, as all factors are prob-
ably linked.
TNF-alpha and TNF-alpha receptors are dynamically reg-
ulated in different pathologic situations. In failing human
hearts TNF-alpha overexpression was one of several maladap-
tive mechanisms responsible for the progressive cardiac de-
compensation (35). Therefore, TNF-alpha might trigger its
self-induction. In other words, the production of TNF-alpha by
the ischemic heart might be a self-amplifying process. Anti-
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TNF mAb might intervene and stop the process. Anti-TNF
mAb binds TNF-alpha and prevents its binding to cell mem-
brane receptors that might be responsible for the further
increase in TNF-alpha synthesis after ischemia. Anti-TNF
mAb might prevent the induction of TNF-alpha in the isch-
emic myocardium in a yet unexplored way. This hypothesis
might explain why there was no immunostaining for TNF-
alpha in the anti-TNF mAb treatment group.
Limitations of the study. The current study was designed
to examine the role of paracrine TNF-alpha in the ischemic
heart. Caution must be taken in withdrawing direct clinical
conclusions from the use of anti-TNF mAb in a clinical setting,
as the model used was an isolated rat heart model and the
experiments were performed in a blood-free environment.
Future studies using blood and neutrophil reperfusion need to
be carried out.
New insights. Our findings of local TNF-alpha synthesis
and release from the isolated ischemic reperfused myocardium
(18) and the protective role of anti-TNF mAb on ischemia-
reperfusion injury in a blood- and leukocyte-free environment
can shed new light on previous hypotheses. In other words,
TNF-alpha does not act only as an important substance in the
recruitment of circulating leukocytes to sites of inflammatory
lesions (9–15,36); it is probably synthesized during ischemia
and released on reperfusion from the myocardium itself.
TNF-alpha possesses a local insult or deleterious effect (myo-
cardial depression) without the essential need for systemic
involvement in this process. By diminishing this deleterious
effect with specific treatment—monoclonal antibodies—
against TNF-alpha, we have presented here unequivocal proof
of the active role of local or paracrine myocardial TNF-alpha
in the evolution of ischemia-reperfusion injury.
All represented data were statistically analyzed by Yael Villa, MSc, School of
Mathematics, Tel-Aviv University. We thank Lynda Hemi for help in preparing
the manuscript.
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